EKF Diagnostics Holdings plc announced the launch of the first PointMan DNA enrichment products, following the acquisition of 360 Genomics Limitedand the establishment of EKF Molecular Diagnostics in March 2013, ahead of plan. The three PointMan kits being launched for the Research Use Only market, with planned diagnostic registration in Europe in 2014, are: PointMan BRAF DNA Enrichment Kit: The BRAF gene has proven utility in the treatment of melanoma as well as colorectal cancer, PointMan KRAS DNA Enrichment Kit: The KRAS gene has proven utility in the treatment of colorectal cancer, PointMan EGFR T790M DNA Enrichment Kit: T790M mutation in EGFR (epidermal growth factor receptor) has been associated with about 50% of patients who develop resistance to EGFR targeted therapies in non-small cell lung cancer. The launch of these three kits, which are the first in a line of further expected PointMan product launches, comes ahead of schedule and represents step one operational development plan for the newly established EKF Molecular Diagnostics.

EKF Diagnostics Holdings plc, Annual General Meeting, May 15, 2013., at 14:00 GMT Standard Time. Location: Canaccord Genuity Limited.

EKF Diagnostics Holdings plc reported consolidated earnings results for the year ended December 31, 2012. For the period, the company reported revenue of £26,060,000 compared with £21,658,000 for the same period last year. Operating profit was £204,000 compared with operating loss of £2,040,000 for the same period last year. EBITDA before exceptional items and share-based payment was £3,202,000 compared with £1,568,000 for the same period last year. Loss before income tax was £196,000 compared with £2,360,000 for the same period last year. Profit for the year from continuing operations was £410,000 or 0.09 pence diluted per share compared with loss for the year from continuing operations £2,558,000 or 1.26 pence diluted per share for the same period last year. Profit attributable to Owners of the parent was £1,830,000 or 0.68 pence diluted per share compared with loss attributable to Owners of the parent £2,884,000 or 1.35 pence diluted per share for the same period last year. Net cash generated by operating activities was £1,599,000 compared with net cash used in operating activities £806,000 for the same period last year. Purchase of property, plant and equipment was £961,000 compared with £1,555,000 for the same period last year. Revenue for the period was increased 20.3%. When comparing revenue on a pro-forma basis including a full year of results for Stanbio for 2011, revenue was flat. This was a result of the large one-off sale to IMSS in the second half of 2011 The company anticipated continued growth throughout 2013. The company continues to execute ambitious growth plan.